Published in Dig Dis Sci on August 08, 2013
Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci (2014) 1.27
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol (1993) 13.16
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA (2008) 5.27
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol (2005) 3.27
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Polypharmacy: misleading, but manageable. Clin Interv Aging (2008) 2.31
Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ (2009) 2.10
Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res (2006) 1.87
Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2010) 1.73
Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology (2010) 1.66
Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology (2008) 1.64
Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol (2010) 1.51
Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol (2011) 1.50
Review and management of drug interactions with boceprevir and telaprevir. Hepatology (2012) 1.42
Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. Aliment Pharmacol Ther (2012) 1.23
Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther (2011) 1.11
Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection. J Clin Gastroenterol (2010) 0.99
Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis. Eur J Health Econ (2011) 0.91
Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic. J Natl Med Assoc (2005) 0.87
Assuring the quality of health care for older persons. An expert panel's priorities. JAMA (1987) 0.86
African americans are less likely to have clearance of hepatitis C virus infection: the findings from recent U.S. population data. J Clin Gastroenterol (2012) 0.80
Polypharmacy: overdosing on good intentions. Manag Care Q (2002) 0.77
Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci (2007) 1.83
Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis (2007) 1.32
Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci (2014) 1.27
High-resolution chromoendoscopy for classifying colonic polyps: a multicenter study. Gastrointest Endosc (2002) 1.14
The frequency of peptic ulcer as a cause of upper-GI bleeding is exaggerated. Gastrointest Endosc (2004) 1.11
Successful nonoperative management of gastrointestinal mucormycosis: novel therapy for invasive disease. Surg Infect (Larchmt) (2009) 1.10
Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation. Chemotherapy (2008) 1.07
Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf (2005) 1.05
Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab Toxicol (2011) 1.05
Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis (2010) 1.00
Pancreatic tuberculosis diagnosed with endoscopic ultrasound guided fine needle aspiration. JOP (2005) 0.99
Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. Arthritis Care Res (Hoboken) (2010) 0.99
Drug-induced liver injury in 2007. Curr Opin Gastroenterol (2008) 0.96
Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol (2010) 0.94
Drug- and chemical-induced cholestasis. Clin Liver Dis (2004) 0.93
Drug-induced liver injury: what was new in 2008? Expert Opin Drug Metab Toxicol (2009) 0.92
Predicting and preventing acute drug-induced liver injury: what's new in 2010? Expert Opin Drug Metab Toxicol (2010) 0.91
Gone (from the Physicians' desk reference) but not forgotten: propylthiouracil-associated hepatic failure: a call for liver test monitoring. J Natl Med Assoc (2010) 0.90
Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic. J Natl Med Assoc (2005) 0.87
Drug-induced liver disease in 2006. Curr Opin Gastroenterol (2007) 0.87
Drug-induced liver disease 2004. Curr Opin Gastroenterol (2005) 0.84
Persistent spontaneous bacterial peritonitis: a common complication in patients with spontaneous bacterial peritonitis and a high score in the model for end-stage liver disease. Therap Adv Gastroenterol (2012) 0.84
Co-management between hospitalist and hepatologist improves the quality of care of inpatients with chronic liver disease. J Clin Gastroenterol (2014) 0.82
Latest advances in predicting DILI in human subjects: focus on biomarkers. Expert Opin Drug Metab Toxicol (2012) 0.81
Sumatriptan-associated ischemic colitis: case report and review of the literature and FAERS. Drug Saf (2014) 0.81
Drug-induced liver disease in 2003. Curr Opin Gastroenterol (2004) 0.80
Dermatologists' awareness of and screening practices for hepatitis B virus infection before initiating tumor necrosis factor-α inhibitor therapy. South Med J (2011) 0.80
Drug-induced liver injury in the elderly. Curr Gastroenterol Rep (2013) 0.79
Hepatotoxicity of antibiotics: a review and update for the clinician. Clin Liver Dis (2013) 0.79
Drug-induced liver injury: what was new in 2013? Expert Opin Drug Metab Toxicol (2014) 0.78
Dobutamine stress echocardiography in patients undergoing orthotopic liver transplantation: a pooled analysis of accuracy, perioperative and long term cardiovascular prognosis. Int J Cardiovasc Imaging (2013) 0.78
Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials. Drug Saf (2014) 0.78
Fatal varicella-zoster hepatitis presenting with severe abdominal pain: a case report and review of the literature. Dig Dis Sci (2006) 0.77
Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant (2012) 0.76
Diagnosis: Liver biopsy differentiates DILI from autoimmune hepatitis. Nat Rev Gastroenterol Hepatol (2011) 0.76
Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. Ann Pharmacother (2007) 0.76
Drug-induced liver disease. Curr Opin Gastroenterol (2003) 0.75
Did this drug cause my patient's hepatitis? Ann Intern Med (2003) 0.75
How the FDA handles GI drug safety. Am J Gastroenterol (2012) 0.75
Relationship between certain medications and cirrhosis. Am Fam Physician (2007) 0.75
Use of endoclips to obliterate a colonic arteriovenous malformation before cauterization. Gastrointest Endosc (2006) 0.75
The safety of same-day endoscopy and percutaneous liver biopsy. Dig Dis Sci (2010) 0.75